PCa Commentary | Volume 146 – October 2020
This Commentary discusses how radium-223 therapy for mCRPC prolongs survival, improving with earlier use and when combined with other agents.
Read MoreSelect Page
Posted by Edward Weber, MD | Oct 2020
This Commentary discusses how radium-223 therapy for mCRPC prolongs survival, improving with earlier use and when combined with other agents.
Read MorePosted by Una Lee, MD, FPMRS | Oct 2020
Una Lee, MD, FPMRS, urologist and researcher at Virginia Mason Medical Center, reviews the 2019 AUA/SUFU guidelines on uncomplicated recurrent urinary tract infection (rUTI) in women, summarizes the evidence underlying these guidelines, and discusses their relevance to clinical scenarios. She first details complications clinicians may experience, such as antibiotic resistant infections and stressed patients. Dr. Lee then discusses the guideline recommendations: clinicians should use first-line therapy; should obtain urinalysis, urine culture, and sensitivity; may offer patient-initiated treatment; should use as short a duration of antibiotics as possible; may offer cranberry prophylaxis for women with rUTIs; should obtain a full patient history; and should not treat asymptomatic bacteriuria. She then argues that although molecular diagnostics are available, the sensitive microorganism detection they provide is associated with overtreatment, overdiagnosis, and confusion due to our current lack of data on which microorganisms are necessary or harmful for a healthy urinary microbiome. Dr. Lee concludes by discussing cranberries and the treatment capabilities of the proanthocyanidins (PACs) they contain, noting that antibiotics are still considered to be more effective, however.
Read MorePosted by Edward Weber, MD | Sep 2020
PCa Commentary | Volume 145 – September 2020 Posted by Edward Weber | September 2020 PSA,...
Read MorePosted by Daniel W. Lin, MD | Aug 2020
Daniel W. Lin, MD, Chief of Urologic Oncology at the University of Washington, discusses improving the specificity of PSA screening using serum and urine markers to determine which patients do not need a prostate biopsy. He lists the ideal biomarker characteristics, including sensitivity and specificity, correlation with disease outcome, reproducibility, low cost, quick and easy assay, and high negative predictive value. He then discusses some of the major studies done on pre-diagnosis biomarkers for prostate cancer, highlighting how PHI score, 4Kscore, and PCA3, among other markers, all significantly reduce the biopsy rate compared with older diagnostics like percent free PSA. Dr. Lin concludes by noting how urologists can further reduce unnecessary biopsies through smart screening strategies, including biennial rather than annual PSA screenings and considering not biopsying men with low early PSA scores.
Read MorePosted by Edward Weber, MD | Aug 2020
PCa Commentary | Volume 144 – August 2020 Posted by Edward Weber | August 2020 THE...
Read More